Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PROSPECTIVE RANDOMIZED, DOUBLE-BLIND, COMPARATIVE, MULTICENTER STUDY TO EVALUATE EFFICACY AND SAFETY OF NYSTATIN AND AMPHOTERICIN B FOR EMPIRIC ANTIFUNGAL TREATMENT IN NEUTROPENIC PATIENTS

NCT00002742 is registered in ClinicalTrials.gov with Aronex Pharmaceuticals as lead sponsor.

NCT NCT00002742
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00002742 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PROSPECTIVE RANDOMIZED, DOUBLE-BLIND, COMPARATIVE, MULTICENTER STUDY TO EVALUATE EFFICACY AND SAFETY OF NYSTATIN AND AMPHOTERICIN B FOR EMPIRIC ANTIFUNGAL TREATMENT IN NEUTROPENIC PATIENTS
Lead sponsor
Aronex Pharmaceuticals
Phase
Phase 3
Overall status
Completed
Start date
January 31, 1996
Completion date
September 30, 2007
Enrollment
Not reported
Sites
59

Conditions

As the registry lists them; a condition with its own page is linked.

chronic myeloproliferative disorders, infection, leukemia, lymphoma, multiple myeloma and plasma cell neoplasm, myelodysplastic syndromes